Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

121 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A plasma metabolomic signature discloses human breast cancer.
Jové M, Collado R, Quiles JL, Ramírez-Tortosa MC, Sol J, Ruiz-Sanjuan M, Fernandez M, de la Torre Cabrera C, Ramírez-Tortosa C, Granados-Principal S, Sánchez-Rovira P, Pamplona R. Jové M, et al. Oncotarget. 2017 Mar 21;8(12):19522-19533. doi: 10.18632/oncotarget.14521. Oncotarget. 2017. PMID: 28076849 Free PMC article.
Safety and efficacy of neo-adjuvant sequential dose-dense chemotherapy doublets combined with trastuzumab in patients with HER-2-positive early stage breast cancer.
Sánchez-Muñoz A, García-Tapiador AM, Dueñas-García R, Jaén-Morago A, Ortega-Granados AL, Martínez-Ortega E, Fernández Morales M, Fernández-Navarro M, de la Torre Cabrera C, Dueñas B, Ureña C, Martínez J, Morales F, Ramírez-Tortosa C, Sánchez-Rovira P. Sánchez-Muñoz A, et al. Breast J. 2008 Sep-Oct;14(5):506-7. doi: 10.1111/j.1524-4741.2008.00634.x. Epub 2008 Aug 13. Breast J. 2008. PMID: 18705667 No abstract available.
Tumour molecular subtyping according to hormone receptors and HER2 status defines different pathological complete response to neoadjuvant chemotherapy in patients with locally advanced breast cancer.
Sánchez-Muñoz A, García-Tapiador AM, Martínez-Ortega E, Dueñas-García R, Jaén-Morago A, Ortega-Granados AL, Fernández-Navarro M, de la Torre-Cabrera C, Dueñas B, Rueda AI, Morales F, Ramírez-Torosa C, Martín-Salvago MD, Sánchez-Rovira P. Sánchez-Muñoz A, et al. Clin Transl Oncol. 2008 Oct;10(10):646-53. doi: 10.1007/s12094-008-0265-y. Clin Transl Oncol. 2008. PMID: 18940745 Clinical Trial.
Is it possible to increase pCR in the neoadjuvant treatment with a dose-dense/sequential combination?: results from a phase II Trial combining epirubicin and cyclophosphamide followed by paclitaxel and gemcitabine ± trastuzumab in stage II and III breast cancer patients.
Sánchez-Muñoz A, Dueñas-García R, Jaén-Morago A, Carrasco E, Chacón I, García-Tapiador AM, Ortega-Granados AL, Martínez-Ortega E, Ribelles N, Fernández-Navarro M, de la Torre-Cabrera C, Dueñas B, Rueda AI, Martínez J, Tortosa CR, Martín-Salvago MD, Sánchez-Rovira P. Sánchez-Muñoz A, et al. Am J Clin Oncol. 2010 Oct;33(5):432-7. doi: 10.1097/COC.0b013e3181b4eff9. Am J Clin Oncol. 2010. PMID: 19952716 Clinical Trial.
121 results